Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 8, keine Gesamtzahl für „Substances“
Suchtreffer
Begriffe & Kennungen
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.3 · Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · Medicinal product by therapeutic Effects on active substances levels Recommendation concerning areas Mean perc
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Mylan · 4.3 · Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Zentiva · 4.3 · Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Eintrag öffnenEfficib · 4.3 · - hypersensitivity to the active substances or to any of the excipients listed in section 6.1 (see sections 4.
Eintrag öffnenElebrato Ellipta · 4.3 · 3 Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Eintrag öffnenEliquis · 4.5 · Active substances which are not considered strong inhibitors of both CYP3A4 and P-gp, (e.g., amiodarone, clari
Eintrag öffnenEliquis · 4.5 · Active substances which are not considered strong inhibitors of both CYP3A4 and P-gp, (e.g., amiodarone, clari
Eintrag öffnenEliquis · 4.5 · Active substances which are not considered strong inhibitors of both CYP3A4 and P-gp, (e.g., amiodarone, clari
Eintrag öffnenEliquis · 4.5 · Active substances which are not considered strong inhibitors of both CYP3A4 and P-gp, (e.g., amiodarone, clari
Eintrag öffnenEmblaveo · 4.3 · Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Eintrag öffnenEmend · 4.5 · Concomitant administration of EMEND with active substances that strongly induce CYP3A4 activity (e.g., rifampi
Eintrag öffnenEmend · 4.5 · Concomitant administration of EMEND with active substances that strongly induce CYP3A4 activity (e.g., rifampi
Eintrag öffnenEmend · 4.5 · Effect aprepitant on the pharmacokinetics of other active substances CYP3A4 inhibition As a moderate inhibitor
Eintrag öffnenEmend · 4.5 · Effect of aprepitant on the pharmacokinetics of other active substances CYP3A4 inhibition As a moderate inhibi
Eintrag öffnenEmselex · 4.5 · CYP2D6 inhibitors In patients receiving substances that are potent CYP2D6 inhibitors (e.g. paroxetine, terbina
Eintrag öffnenEmselex · 4.5 · CYP2D6 inhibitors In patients receiving substances that are potent CYP2D6 inhibitors (e.g. paroxetine, terbina
Eintrag öffnenEmselex · 4.5 · Enzyme inducers Substances that are inducers of CYP3A4, such as rifampicin, carbamazepine, barbiturates and St
Eintrag öffnenEmselex · 4.5 · Enzyme inducers Substances that are inducers of CYP3A4, such as rifampicin, carbamazepine, barbiturates and St
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Krka · 4.3 · Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Eintrag öffnen